Petteri
Rinne
Docent, Institute of Biomedicine
Senior Research Fellow, Institute of Biomedicine
PhD
Links
Areas of expertise
Cardiovascular diseases
Atherosclerosis
Heart Failure
Cardiovascular Pharmacology
Experimental Research
Biography
I work currently as Academy Research Fellow at the University of Turku. I graduated from the Health Biosciences Master's degree programme (University of Turku) with a major in Drug Development. Thereafter, I conducted my PhD studies at the Department of Pharmacology, Drug Development and Therapeutics and graduated in 2013. After doing a short postdoctoral research period at the Turku PET Centre, I was awarded a 3-year postdoctoral fellowship from the Academy of Finland. During this period, I did research at the Institute for Cardiovascular Prevention (IPEK) in Munich, Germany. My current affiliation is Research Center For Integrative Physiology and Pharmacology, Institute of Biomedicine, and my office is located in Medisiina C building.
Teaching
I am actively involved in teaching activities in courses related to basic and advanced pharmacology, particularly in courses in cardiovascular pharmacology. As I am currently holding a research-oriented position, my contribution to teaching is not very extensive, but besides occasional lecturing, I am mentoring as well as supervising undergraduate and PhD students in their thesis projects.
Research
My current research projects focus on the role of melanocortin and lipid signalling in cardiovascular diseases. In particular, the research aims at evaluating the therapeutic potential of targeting these systems for the management of atherosclerosis. We utilize both loss- and gain-of-function models as
well as pharmacological and genetic approaches to advance our understanding of
the roles of these mediators in atherosclerosis. The projects also combine various in vitro and in vivo models to achieve an extensive view
of the underlying molecular-level mechanisms.
Coronary artery disease arising from atherosclerosis is a common form of cardiovascular disease and an important public health challenge worldwide. It is lacking effective treatments that would specifically target and reverse the underlying pathology and disease progression, highlighting the unmet medical need. Our research projects contribute to this need by exploring the possible therapeutic benefits of targeting melanocortin and lipid mediators in atherosclerosis.
Coronary artery disease arising from atherosclerosis is a common form of cardiovascular disease and an important public health challenge worldwide. It is lacking effective treatments that would specifically target and reverse the underlying pathology and disease progression, highlighting the unmet medical need. Our research projects contribute to this need by exploring the possible therapeutic benefits of targeting melanocortin and lipid mediators in atherosclerosis.
Publications
[F-18]FDG Accumulation in Early Coronary Atherosclerotic Lesions in Pigs (2015)
PLoS ONE
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Deficiency in Melanocortin 1 Receptor Signaling Predisposes to Vascular Endothelial Dysfunction and Increased Arterial Stiffness in Mice and Humans (2015)
Arteriosclerosis, Thrombosis, and Vascular Biology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Abstract 15108: Imaging Coronary Atherosclerosis Using [18F]FDG PET-CT: Validation Study in Pigs (2014)
Circulation
(O2 Muu julkaisu )
The effects of equal caloric high fat and western diet on metabolic syndrome, oxidative stress and vascular endothelial function in mice (2014)
Acta Physiologica
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Pharmacological activation of the melanocortin system limits plaque inflammation and ameliorates vascular dysfunction in atherosclerotic mice (2014)
Arteriosclerosis, Thrombosis, and Vascular Biology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
α-MSH overexpression in the nucleus tractus solitarius decreases fat mass and elevates heart rate. (2014)
Journal of Endocrinology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Pharmacological treatment with a melanocortin analogue protects against pressure-overload-induced cardiac hypertrophy (2013)
FASEB Journal
(O2 Muu julkaisu )
alpha-MSH Analogue Attenuates Blood Pressure Elevation in DOCA-Salt Hypertensive Mice (2013)
PLoS ONE
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
α-Melanocyte-stimulating hormone regulates vascular NO availability and protects against endothelial dysfunction (2013)
Cardiovascular Research
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Genetic and pharmacological mouse models of chronic melanocortin activation show enhanced baroreflex control of heart rate (2013)
Regulatory Peptides
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))